Suven Life Sciences : Schedule of Conference Call for Investors on December 26, 2022
December 28, 2022 at 11:43 am
Share
CSD/BSE&NSE/CC/2022-23
December 26, 2022
To
To
The Manager
The Manager
Department of Corporate Services
Listing Department
BSE Limited
National Stock Exchange of India Limited
25th Floor, P. J. Towers,
Exchange Plaza, Bandra Kurla Complex
Dalal Street, Mumbai - 400 001
Bandra (E), Mumbai - 400 051
Scrip Code: 543064
Scrip Symbol: SUVENPHAR
Dear Sir/Madam,
Sub: Schedule of Conference Call for Investors
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on today i.e. Monday, December 26, 2022 at 2:30 PM IST to discuss today's announcement that Advent International is to acquire a significant stake in Suven Pharmaceuticals from the Jasti Family.
This is for your information and record.
Thanking You,
Yours faithfully,
For Suven Pharmaceuticals Limited
Digitally signed by:
HANUMANTHANUMANTHA RAO
HA RAO
KOKKONDA
DN: CN = HANUMANTHA RAO
KOKKONDA email =
KHRAO@SUVENPHARM.COM C
KOKKONDADate: 2022.12.26 10:24:23 +05'30'
= IN O = Personal
K Hanumantha Rao
Company Secretary
Encl: as above
Suven Pharmaceuticals Limited
Registered Office: # 8-2-334 I SDE Serene Chambers I 3rd Floor I Road No.5
Avenue 7 I Banjara Hills I Hyderabad - 500034 I Telangana I India I CIN: L24299TG2018PLC128171
Tel: 91 40 2354 9414 /1142 /3311 I Fax: 91 40 2354 1152 I Email: info@suvenpharm.com I www.suvenpharm.com
Suven Pharmaceuticals Ltd to host Conference call Today,
December 26, 2022 @ 2.30 pm IST
Suven Pharmaceuticals Ltd will be conducting a conference call to discuss today's announcement that Advent International is to acquire a significant stake in Suven Pharmaceuticals from the Jasti family. Suven Pharmaceuticals Ltd will be represented by members of the senior management team.
The conference call will be initiated with a brief discussion after which the floor will be opened for Q&As.
In order to pre-register: Copy this URL in your browser:
Suven Life Sciences Limited published this content on 26 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 December 2022 11:20:21 UTC.
Suven Life Sciences Limited is an India-based biopharmaceutical company. The Company is engaged in the drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. It operates through the research and development services segment. Its drug discovery & research/clinical pipeline include Masupirdine (SUVN-502) Neuropsychiatric Symptoms in Alzheimer's, Masupirdine (SUVN-502) Cognitive deficits in AD, Samelisant (SUVN-G3031) Narcolepsy, Samelisant (SUVN-G3031) Cognitive Disorders, Ropanicant (SUVN-911) Depressive Disorders, Usmarapride (SUVN-D4010), Cognitive Disorders, SUVN-I6107, Cognitive Disorders and Schizophrenia, SUVN-M8036, Psychiatric Disorders, and SUVN-D1044 Gastrointestinal Disorders. Its drug discovery & development support services (DDDSS) include synthetic and medicinal chemistry, analytical chemistry, in vitro biology, ADME, pharmacology, toxicology, bioanalysis, and NCE formulations.